Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization

Journal of General Virology

Volumn 93, Issue PART 7, 2012, Pages 1495-1505

  Thenin, Suzie ^a   Roch, Emmanuelle ^a   Samleerat, Tanawan ^a,b   Moreau, Thierry ^a   Chaillon, Antoine ^a   Moreau, Alain ^a   Barin, Francis ^a   Braibant, Martine ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLUTAMIC ACID; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ISOLEUCINE; LYSINE; METHIONINE; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PG9; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; INFANT; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DNA MUTATIONAL ANALYSIS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION, MISSENSE; NEUTRALIZATION TESTS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 84862681126     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.042614-0     Document Type: Article

References (36)

1. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H. & other authors (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6, 200-206.
2. Barouch, D. H. (2008). Challenges in the development of an HIV-1 vaccine. Nature 455, 613-619.
3. Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L. & other authors (2008). Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82, 11651-11668.
4. Bonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H. & other authors (2011). Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85, 9998-10009.
5. Braibant, M., Agut, H., Rouzioux, C., Costagliola, D., Autran, B. & Barin, F. (2008). Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies. J Acquir Immune Defic Syndr 47, 274-284.
6. Braibant, M., Xie, J., Samri, A., Agut, H., Autran, B. & Barin, F. (2010). Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology 405, 81-92.
7. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A. & Wyatt, R. T. (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5, 233-236.
8. Burton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., Dunlop, D. C., Poignard, P., Doyle, L. A. & other authors (2011). Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 108, 11181-11186.
9. Chaillon, A., Braibant, M., Moreau, T., Thenin, S., Moreau, A., Autran, B. & Barin, F. (2011). The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J Virol 85, 3642-3648.
10. Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. (1995). Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935-944.
11. Corti, D., Langedijk, J. P. M., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D. & other authors (2010). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5, e8805.
12. Doores, K. J. & Burton, D. R. (2010). Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84, 10510-10521.
13. Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A. & Burton, D. R. (2009a). Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15, 951-954.
14. Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I. & Burton, D. R. (2009b). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5, e1000433.
15. Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., Forthal, D. N., Koff, W. C., Poignard, P. & other authors (2010). Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84, 1302-1313.
16. Lallemant, M., Jourdain, G., Le Coeur, S., Kim, S., Koetsawang, S., Comeau, A. M., Phoolcharoen, W., Essex, M., McIntosh, K., Vithayasai, V. & Perinatal HIV Prevention Trial (Thailand) Investigators (2000). A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 343, 982-991.
17. Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M. & other authors (2007). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13, 1032-1034.
18. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. & Subramaniam, S. (2008). Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113.
19. Mascola, J. R. (2003). Defining the protective antibody response for HIV-1. Curr Mol Med 3, 209-216.
20. Mascola, J. R. & Montefiori, D. C. (2010). The role of antibodies in HIV vaccines. Annu Rev Immunol 28, 413-444.
21. Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V. & other authors (1999). Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73, 4009-4018.
22. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S. & other authors (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6, 207-210.
23. McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M. & other authors (2011). Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343.
24. Parren, P. W., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P. & Burton, D. R. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75, 8340-8347.
25. Samleerat, T., Braibant, M., Jourdain, G., Moreau, A., Ngo-Giang-Huong, N., Leechanachai, P., Hemvuttiphan, J., Hinjiranandana, T., Changchit, T. & other authors (2008). Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J Infect Dis 198, 868-876.
26. Samleerat, T., Thenin, S., Jourdain, G., Ngo-Giang-Huong, N., Moreau, A., Leechanachai, P., Ithisuknanth, J., Pagdi, K., Wannarit, P. &other authors (2009). Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387, 388-394.
27. Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D. & Moore, J. P. (2002). The mannosedependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76,7293-7305.
28. Scanlan, C. N., Pantophlet, R., Wormald, M. R., Ollmann Saphire, E., Stanfield, R., Wilson, I. A., Katinger, H., Dwek, R. A., Rudd, P. M. & Burton, D. R. (2002). The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1A2 mannose residues on the outer face of gp120. J Virol 76, 7306-7321.
29. Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A. & other authors (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637.
30. Thenin, S., Samleerat, T., Tavernier, E., Ngo-Giang-Huong, N., Jourdain, G., Lallemant, M., Barin, F. & Braibant, M. (2012). Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties. Virology 426, 12-21.
31. Walker, L. M. & Burton, D. R. (2010). Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22, 358-366.
32. Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S. & other authors (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289.
33. Walker, L. M., Simek, M. D., Priddy, F., Gach, J. S., Wagner, D., Zwick, M. B., Phogat, S. K., Poignard, P. & Burton, D. R. (2010). A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6, e1001028.
34. Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y. & other authors (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470.
35. Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L. & other authors (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861.
36. Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W. & other authors (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817.